Amino acid Infusion to improve Renal outcomes after Pulmonary Organ Transplantation [AIRPORT Study] (ACTRN12625001381471)

Acute kidney injury (AKI) occurs in two-thirds of patients after lung transplantation, even in patients who usually have normal kidney function. Amino acids are the 'building blocks' of protein and can be given as nutritional supplements. More recently they have been shown to be effective in preventing kidney damage in cardiac surgery. We think they may also help in lung transplantation by improving renal blood flow, which is why we are carrying out this study. Synthamin-17 is a liquid medicine that contains amino acids which can be given into veins as a form of nutritional supplement in patients who can't absorb proteins from the gut.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

A/Prof Tim Coulson

Key inclusion data

Inclusion criteria: All adult patients undergoing lung transplantation. Exclusion criteria: Current or planned dialysis, Combined lung and kidney transplant, or combined lung and liver transplant, Prior kidney transplant Known allergy to one of the amino acids, Congenital abnormality of amino acid metabolism.